A randomized, double-blind, placebo controlled, multi-centre, phase IIA study to assess the effect on GERD symptoms, pharmacokinetics, safety and tolerability of four weeks treatment with AZD3355 65 mg bid as add-on treatment to a PPI in patients with an

To estimate the effect of AZD3355 65 mg twice daily (bid) as add-on treatment to a Proton Pump Inhibitor (PPI) on GERD symptoms in patients with an incomplete response to PPI treatment with respect to improvement of each of the patient reported symptoms: - a burning feeling behind the breastbone (heartburn) - unpleasant movement of material upwards from the stomach (regurgitation)